Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy

Sanofi, which already has messenger RNA R&D alliances with other companies, paid $160 million up front to acquire preclinical startup Tidal Therapeutics. The pharma giant said Tidal’s mRNA approach could lead to an off-the-shelf CAR-T therapy.